The Pharmacy Times® HIV Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of HIV, a virus that attacks the body's immune system and, if left untreated, can lead to AIDS.
May 23rd 2025
Pharmacy students must have a comprehensive understanding of antiretrovirals to ensure efficiency and optimization of patients’ medical treatment.
Pharmacist Services to Populations at Risk for HIV: Improving Access and Uptake of Preexposure Prophylaxis
1.0 Credit / HIV/AIDS
View More
Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Ac...
1.5 Credits / HIV/AIDS, Infectious Diseases
View More
Treatment Decision-Making for Complex Patients With HIV: Drug Resistance, Adverse Effects, Comorbidities and P...
1.5 Credits / HIV/AIDS
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Exploring HIV Long-Acting Injectable Uptake: How Pharmacists Can Encourage Long-Acting Injectables to Stem the...
1.5 Credits / HIV/AIDS, Infectious Disease
View More
Study: New Mobile Intervention Application May Reduce HIV Risk Among Same-Sex Attracted Young Males
September 29th 2022Research suggests that HIV risk-reduction interventions could help adolescent males who are attracted to the same sex—and part of a minority ethnic and racial group—decrease HIV-risk sexual behaviors in the short-term.
Read More
Study: Refundable State-Level Earned Income Tax Credit Could Decrease High-Risk HIV Behavior
September 9th 2022A refundable state-level earned income tax credit was associated with a 21% reduction in high-risk HIV behavior among low-income women last year, suggesting that policy can reduce this burden.
Read More
Study: Dolutegravir-based Antiretroviral Therapies for HIV-1 Effective in Pregnancy
September 7th 2022Dolutegravir is a more recently approved ART that is a part of a once-a-day regimen found to be more effective, easier to tolerate, and less likely to create new drug resistance in people with HIV-1 compared with other antiretroviral drugs.
Read More